

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10533622
	Filing Date		2006-01-17
	First Named Inventor	Judy Lieberman	
	Art Unit	1635	
	Examiner Name		
Attorney Docket Number		033393-055194	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20070077563	A1	2007-08-25	Takashi et al.	371 U.S. national stage entry with English translation of WO2005/021752

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	03/099298	WO	A1	2003-12-04	Max-Planck Gesellschaft		<input type="checkbox"/>
	2	2005/021752	WO	A1	2005-10-03	Takara Bio Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. Add

NON-PATENT LITERATURE DOCUMENTS								Remove
---------------------------------	--	--	--	--	--	--	--	--------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10533622
Filing Date	2006-01-17
First Named Inventor	Judy Lieberman
Art Unit	1635
Examiner Name	
Attorney Docket Number	033393-055194

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	LIEBERMAN, J. et al, "Interfering with disease: opportunities and roadblocks to harnessing RNA interference", Trends in Molecular Medicine 9(9):397-403, 2003.	<input type="checkbox"/>
	2	ZHANG, D. et al., "Physical and Functional Interaction between Myeloid Cell Leukemia 1 Protein (MCL1) and Fortilin", J Bio Chem 277(40):37430-37436, 2002.	<input type="checkbox"/>
	3	WANG, J. et al., "Fas siRNA Reduces Apoptotic Cell Death of Allogeneic-Transplanted Hepatocytes in Mouse Spleen", Transplantation Proceedings 35:1594-1595, 2003.	<input type="checkbox"/>
	4	ZHANG, H. et al., "Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis", Nature Biotechnology 18:862-867, 2000.	<input type="checkbox"/>
	5	ZENDER, L. et al., "Caspase 8 small interfering RNA prevents acute liver failure in mice", PNAS 100(13):7797-7802, 2003.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.